http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 13 Feb 2026 17:28:00 +0000 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Estrella+Immunopharma%2C+++++++++++++++/26002183.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260213/AV2JJ22CLC22NT2V222M2ZY2N35TZ222Z282">http://archive.fast-edgar.com/20260213/AV2JJ22CLC22NT2V222M2ZY2N35TZ222Z282</a></p> <p> Filed on: February 13, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Estrella+Immunopharma%2C+++++++++++++++/26002183.html Fri, 13 Feb 2026 17:28:00 +0000 ESLA O.52433315 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Estrella+Immunopharma%2C+++++++++++++++/26002183.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260213/AV2JJ22CLC22NT2V222M2ZY2N35TZ222Z282">http://archive.fast-edgar.com/20260213/AV2JJ22CLC22NT2V222M2ZY2N35TZ222Z282</a></p> <p> Filed on: February 13, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Estrella+Immunopharma%2C+++++++++++++++/26002183.html Fri, 13 Feb 2026 17:28:00 +0000 ESLA O.52433315 http://www.streetinsider.com/Corporate+News/Estrella+Immunopharma+reports+positive+phase+1+data+for+cancer+therapy/25964657.html <p>Estrella Immunopharma Inc. (NASDAQ: ESLA) presented clinical data from its ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma at the 2026 ASTCT & CIBMTR Tandem Meetings.</p><p>In the dose escalation portion of the trial, EB103 demonstrated a 100% Complete Response rate in the high-dose cohort at Month 1, according to the company's press release. All patients who achieved a complete response have remained in complete response through the data cutoff. The median duration of complete response has not been reached, with response durations currently ranging from 3 to 18 months.</p><p>The study included a complete http://www.streetinsider.com/Corporate+News/Estrella+Immunopharma+reports+positive+phase+1+data+for+cancer+therapy/25964657.html Mon, 09 Feb 2026 07:01:19 +0000 ESLA ESLAW http://www.streetinsider.com/Corporate+News/Estrella+Immunopharma+reports+positive+phase+1+data+for+cancer+therapy/25964657.html <p>Estrella Immunopharma Inc. (NASDAQ: ESLA) presented clinical data from its ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma at the 2026 ASTCT & CIBMTR Tandem Meetings.</p><p>In the dose escalation portion of the trial, EB103 demonstrated a 100% Complete Response rate in the high-dose cohort at Month 1, according to the company's press release. All patients who achieved a complete response have remained in complete response through the data cutoff. The median duration of complete response has not been reached, with response durations currently ranging from 3 to 18 months.</p><p>The study included a complete http://www.streetinsider.com/Corporate+News/Estrella+Immunopharma+reports+positive+phase+1+data+for+cancer+therapy/25964657.html Mon, 09 Feb 2026 07:01:19 +0000 ESLA ESLAW http://www.streetinsider.com/FDA/Estrella+Immunopharma+reports+positive+phase+1+data+for+cancer+therapy/25964657.html <p>Estrella Immunopharma Inc. (NASDAQ: ESLA) presented clinical data from its ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma at the 2026 ASTCT & CIBMTR Tandem Meetings.</p><p>In the dose escalation portion of the trial, EB103 demonstrated a 100% Complete Response rate in the high-dose cohort at Month 1, according to the company's press release. All patients who achieved a complete response have remained in complete response through the data cutoff. The median duration of complete response has not been reached, with response durations currently ranging from 3 to 18 months.</p><p>The study included a complete http://www.streetinsider.com/FDA/Estrella+Immunopharma+reports+positive+phase+1+data+for+cancer+therapy/25964657.html Mon, 09 Feb 2026 07:01:19 +0000 ESLA ESLAW http://www.streetinsider.com/FDA/Estrella+Immunopharma+reports+positive+phase+1+data+for+cancer+therapy/25964657.html <p>Estrella Immunopharma Inc. (NASDAQ: ESLA) presented clinical data from its ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma at the 2026 ASTCT & CIBMTR Tandem Meetings.</p><p>In the dose escalation portion of the trial, EB103 demonstrated a 100% Complete Response rate in the high-dose cohort at Month 1, according to the company's press release. All patients who achieved a complete response have remained in complete response through the data cutoff. The median duration of complete response has not been reached, with response durations currently ranging from 3 to 18 months.</p><p>The study included a complete http://www.streetinsider.com/FDA/Estrella+Immunopharma+reports+positive+phase+1+data+for+cancer+therapy/25964657.html Mon, 09 Feb 2026 07:01:19 +0000 ESLA ESLAW http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 +0000 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 +0000 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 +0000 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 +0000 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 +0000 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 +0000 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Press+Releases/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 +0000 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 +0000 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 +0000 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 +0000 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 +0000 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 +0000 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 +0000 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html <p> EMERYVILLE, Calif.--(BUSINESS WIRE)-- <b>Estrella Immunopharma, Inc. (Nasdaq: ESLA, ESLAW)</b> (“Estrella” or the “Company”), a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune diseases, presented positive STARLIGHT-1 Phase I results at the 2026 ASTCT &amp; CIBMTR Tandem Meetings (American Society for Transplantation and Cellular Therapy and Center for International Blood &amp; Marrow Transplant Research). </p><p> The oral presentation highlighted clinical data from the Company’s ongoing STARLIGHT-1 study evaluating EB103, a CD19-redirected ARTEMIS® T-cell therapy, in patients with aggressive B-cell Non-Hodgkin Lymphoma (NHL). In the dose escalation portion of the STARLIGHT-1 trial, EB103 demonstrated http://www.streetinsider.com/Business+Wire/Estrella+Immunopharma+Presents+Promising+Updated+Data+on+EB103+in+Oral+Presentation+at+the+2026+Tandem+Meetings+of+ASTCT%C2%AE+%26amp%3B+CIBMTR%C2%AE/25964588.html Mon, 09 Feb 2026 07:00:00 +0000 A.16120473 A.60012014 ESLA ESLAW O.02893384 O.40440380 O.52433315 http://www.streetinsider.com/FDA/Estrella+Immunopharma+to+present+EB103+phase+1+data+at+2026+ASTCT+meeting/25934580.html <p>Estrella Immunopharma Inc. (NASDAQ: ESLA) announced it will present phase 1 clinical data for its experimental cancer treatment EB103 at the 2026 ASTCT & CIBMTR Tandem Meetings in February.</p> <p>The presentation will feature results from the company's ongoing STARLIGHT-1 study, which evaluates EB103 in patients with aggressive B-cell Non-Hodgkin Lymphoma. EB103 is a CD19-targeted T-cell therapy that uses ARTEMIS technology licensed from Eureka Therapeutics Inc., Estrella's parent company.</p> <p>The late-breaking oral presentation is scheduled for February 7, 2026, at 3:15 p.m. MST during the Late Breaking Abstracts session. Dr. Naseem Esteghamat will present the findings. The abstract will be available on the http://www.streetinsider.com/FDA/Estrella+Immunopharma+to+present+EB103+phase+1+data+at+2026+ASTCT+meeting/25934580.html Tue, 03 Feb 2026 08:00:58 +0000 A.50214643 A.60012014 ESLA O.35847762 O.40440380 O.52433315 http://www.streetinsider.com/FDA/Estrella+Immunopharma+to+present+EB103+phase+1+data+at+2026+ASTCT+meeting/25934580.html <p>Estrella Immunopharma Inc. (NASDAQ: ESLA) announced it will present phase 1 clinical data for its experimental cancer treatment EB103 at the 2026 ASTCT & CIBMTR Tandem Meetings in February.</p> <p>The presentation will feature results from the company's ongoing STARLIGHT-1 study, which evaluates EB103 in patients with aggressive B-cell Non-Hodgkin Lymphoma. EB103 is a CD19-targeted T-cell therapy that uses ARTEMIS technology licensed from Eureka Therapeutics Inc., Estrella's parent company.</p> <p>The late-breaking oral presentation is scheduled for February 7, 2026, at 3:15 p.m. MST during the Late Breaking Abstracts session. Dr. Naseem Esteghamat will present the findings. The abstract will be available on the http://www.streetinsider.com/FDA/Estrella+Immunopharma+to+present+EB103+phase+1+data+at+2026+ASTCT+meeting/25934580.html Tue, 03 Feb 2026 08:00:58 +0000 A.50214643 A.60012014 ESLA O.35847762 O.40440380 O.52433315 http://www.streetinsider.com/FDA/Estrella+Immunopharma+to+present+EB103+phase+1+data+at+2026+ASTCT+meeting/25934580.html <p>Estrella Immunopharma Inc. (NASDAQ: ESLA) announced it will present phase 1 clinical data for its experimental cancer treatment EB103 at the 2026 ASTCT & CIBMTR Tandem Meetings in February.</p> <p>The presentation will feature results from the company's ongoing STARLIGHT-1 study, which evaluates EB103 in patients with aggressive B-cell Non-Hodgkin Lymphoma. EB103 is a CD19-targeted T-cell therapy that uses ARTEMIS technology licensed from Eureka Therapeutics Inc., Estrella's parent company.</p> <p>The late-breaking oral presentation is scheduled for February 7, 2026, at 3:15 p.m. MST during the Late Breaking Abstracts session. Dr. Naseem Esteghamat will present the findings. The abstract will be available on the http://www.streetinsider.com/FDA/Estrella+Immunopharma+to+present+EB103+phase+1+data+at+2026+ASTCT+meeting/25934580.html Tue, 03 Feb 2026 08:00:58 +0000 A.50214643 A.60012014 ESLA O.35847762 O.40440380 O.52433315 http://www.streetinsider.com/FDA/Estrella+Immunopharma+to+present+EB103+phase+1+data+at+2026+ASTCT+meeting/25934580.html <p>Estrella Immunopharma Inc. (NASDAQ: ESLA) announced it will present phase 1 clinical data for its experimental cancer treatment EB103 at the 2026 ASTCT & CIBMTR Tandem Meetings in February.</p> <p>The presentation will feature results from the company's ongoing STARLIGHT-1 study, which evaluates EB103 in patients with aggressive B-cell Non-Hodgkin Lymphoma. EB103 is a CD19-targeted T-cell therapy that uses ARTEMIS technology licensed from Eureka Therapeutics Inc., Estrella's parent company.</p> <p>The late-breaking oral presentation is scheduled for February 7, 2026, at 3:15 p.m. MST during the Late Breaking Abstracts session. Dr. Naseem Esteghamat will present the findings. The abstract will be available on the http://www.streetinsider.com/FDA/Estrella+Immunopharma+to+present+EB103+phase+1+data+at+2026+ASTCT+meeting/25934580.html Tue, 03 Feb 2026 08:00:58 +0000 A.50214643 A.60012014 ESLA O.35847762 O.40440380 O.52433315 http://www.streetinsider.com/FDA/Estrella+Immunopharma+to+present+EB103+phase+1+data+at+2026+ASTCT+meeting/25934580.html <p>Estrella Immunopharma Inc. (NASDAQ: ESLA) announced it will present phase 1 clinical data for its experimental cancer treatment EB103 at the 2026 ASTCT & CIBMTR Tandem Meetings in February.</p> <p>The presentation will feature results from the company's ongoing STARLIGHT-1 study, which evaluates EB103 in patients with aggressive B-cell Non-Hodgkin Lymphoma. EB103 is a CD19-targeted T-cell therapy that uses ARTEMIS technology licensed from Eureka Therapeutics Inc., Estrella's parent company.</p> <p>The late-breaking oral presentation is scheduled for February 7, 2026, at 3:15 p.m. MST during the Late Breaking Abstracts session. Dr. Naseem Esteghamat will present the findings. The abstract will be available on the http://www.streetinsider.com/FDA/Estrella+Immunopharma+to+present+EB103+phase+1+data+at+2026+ASTCT+meeting/25934580.html Tue, 03 Feb 2026 08:00:58 +0000 A.50214643 A.60012014 ESLA O.35847762 O.40440380 O.52433315